Skip to main content
Fig. 1 | BMC Medicine

Fig. 1

From: Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial

Fig. 1

Participant flow diagram. Randomization and analysis populations. A total of 783 participants were enrolled, and 483 received booster vaccinations. The participants were randomly assigned to receive a booster dose of either RCP or BBIBP-CorV. All the 483 participants receiving booster vaccination were included in the safety set for safety analysis. We evaluated the immunogenicity in 417 participants who visited the research center for blood sampling on day 14 and a subgroup of 101 participants on 3 and 6 months after the booster dose

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us